Neuromodulation in Tourette syndrome: Dopamine and beyond

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 6, 2013, Pages 1069-1084

  Buse, Judith ^a   Schoenefeld, Katja ^a   Münchau, Alexander ^b   Roessner, Veit ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Dopamine, CSTC; Neurochemistry; Tourette syndrome

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERDOMAPINERGIC DISORDER; HYPODOMAPINERGIC DISORDER; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SENSORIMOTOR INTEGRATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; METABOLISM; NEUROIMAGING; PATHOLOGY; SYNAPTIC TRANSMISSION; TOURETTE SYNDROME;

DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; NEUROIMAGING; NEUROTRANSMITTER AGENTS; SYNAPTIC TRANSMISSION; TOURETTE SYNDROME;

EID: 84886692670     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.10.004     Document Type: Review

References (206)

1. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., Minoshima S., Kilbourn M.R., Frey K.A. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003, 61:310-315.
2. Albin R.L., Koeppe R.A., Wernette K., Zhuang W., Nichols T., Kilbourn M.R., Frey K.A. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology 2009, 72:1390-1396.
3. Allman A.-A., Benkelfat C., Durand F., Sibon I., Dagher A., Leyton M., Baker G.B., O'Driscoll G.A. Effect of d-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berlin) 2010, 211:423-433.
4. Anca M.H., Giladi N., Korczyn A.D. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004, 62:1626-1627.
5. Avanzino L., Martino D., Bove M., De Grandis E., Tacchino A., Pelosin E., Mirabelli M., Veneselli E., Abbruzzese G. Movement lateralization and bimanual coordination in children with Tourette syndrome. Movement Disorders 2011, 26:2114-2118.
6. Barch D.M. Pharmacological manipulation of human working memory. Psychopharmacology (Berlin) 2004, 174:126-135.
7. Beaulieu J.-M., Gainetdinov R.R. The physiology signaling, and pharmacology of dopamine receptors. Pharmacological Reviews 2011, 63:182-217.
8. Ben-Dor D.H., Zimmerman S., Sever J., Roz N., Apter A., Rehavi M., Weizman A. Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients. European Neuropsychopharmacology 2007, 17:523-526.
9. Black K.J., Mink J.W. Response to levodopa challenge in Tourette syndrome. Movement Disorders 2000, 15:1194-1198.
10. Bloch M., State M., Pittenger C. Recent advances in Tourette syndrome. Current Opinion in Neurology 2011, 24:119-125.
11. Bornstein R.A., Stefl M.E., Hammond L. A survey of Tourette syndrome patients and their families: the 1987 Ohio Tourette Survey. Journal of Neuropsychiatry & Clinical Neurosciences 1990, 2:275-281.
12. Borowsky B., Kuhn C.M. D1 and D2 dopamine receptors stimulate hypothalamo-pituitary-adrenal activity in rats. Neuropharmacology 1992, 31:671-678.
13. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia human and animal model studies. Archives of General Psychiatry 1990, 47:181-188.
14. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects patient groups, and pharmacological studies. Psychopharmacology (Berlin) 2001, 156:234-258.
15. Castellanos F.X., Elia J., Kruesi M.J., Marsh W.L., Gulotta C.S., Potter W.Z., Ritchie G.F., Hamburger S.D., Rapoport J.L. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 1996, 14:125-137.
16. Castellanos F.X., Fine E.J., Kaysen D., Marsh W.L., Rapoport J.L., Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biological Psychiatry 1996, 39:33-41.
17. Castiello U., Bennett K.M., Bonfiglioli C., Peppard R.F. The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication. Neuropsychologia 2000, 38:46-59.
18. Chappell P., Leckman J., Goodman W., Bissette G., Pauls D., Anderson G., Riddle M., Scahill L., McDougle C., Cohen D. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39:776-783.
19. Chappell P., Riddle M., Anderson G., Scahill L., Hardin M., Walker D., Cohen D., Leckman J. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry 1994, 36:35-43.
20. Cheon K.-A., Ryu Y.-H., Namkoong K., Kim C.-H., Kim J.-J., Lee J.D. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Research 2004, 130:85-95.
21. Cheung S., Ballew J.R., Moore K.E., Lookingland K.J. Contribution of dopamine neurons in the medial zona incerta to the innervation of the central nucleus of the amygdala, horizontal diagonal band of Broca and hypothalamic paraventricular nucleus. Brain Research 1998, 808:174-181.
22. Conelea C.A., Woods D.W. The influence of contextual factors on tic expression in Tourette's syndrome: a review. Journal of Psychosomatic Research 2008, 65:487-496.
23. Cools R., Barker R.A., Sahakian B.J., Robbins T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cerebral Cortex 2001, 11:1136-1143.
24. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry 2011, 69:e113-e125.
25. Corbett B.A., Mendoza S.P., Baym C.L., Bunge S.A., Levine S. Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. Psychoneuroendocrinology 2008, 33:810-820.
26. Cragg S.J., Rice M.E. DAncing past the DAT at a DA synapse. Trends in Neurosciences 2004, 27:270-277.
27. Csomor P.A., Stadler R.R., Feldon J., Yee B.K., Geyer M.A., Vollenweider F.X. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 2008, 33:497-512.
28. Davis M., Mansbach R.S., Swerdlow N.R., Campeau S., Braff D.L., Geyer M.A. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. Psychopharmacology (Berlin) 1990, 102:1-4.
29. de Wit H., Crean J., Richards J.B. Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behavioral Neuroscience 2000, 114:830-837.
30. Del Arco A., Mora F. Dopamine release in the prefrontal cortex during stress is reduced by the local activation of glutamate receptors. Brain Research Bulletin 2001, 56:125-130.
31. Del Arco A., Segovia G., Garrido P., de Blas M., Mora F. Stress prefrontal cortex and environmental enrichment: studies on dopamine and acetylcholine release and working memory performance in rats. Behavioural Brain Research 2007, 176:267-273.
32. Del Arco A., Segovia G., Mora F. Dopamine release during stress in the prefrontal cortex of the rat decreases with age. Neuroreport 2001, 12:4019-4022.
33. Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biological Psychiatry 2011, 69:145-157.
34. Eaton M.J., Cheung S., Moore K.E., Lookingland K.J. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Research 1996, 738:60-66.
35. Erenberg G., Cruse R.P., Rothner A.D. Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 1985, 35:1346-1348.
36. Ernst M., Zametkin A.J., Jons P.H., Matochik J.A., Pascualvaca D., Cohen R.M. High presynaptic dopaminergic activity in children with Tourette's disorder. Journal of the American Academy of Child & Adolescent Psychiatry 1999, 38:86-94.
37. Feenstra M.G., Botterblom M.H., Mastenbroek S. Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens. Neuroscience 2000, 100:741-748.
38. Feenstra M.G., Botterblom M.H., van Uum J.F. Local activation of metabotropic glutamate receptors inhibits the handling-induced increased release of dopamine in the nucleus accumbens but not that of dopamine or noradrenaline in the prefrontal cortex: comparison with inhibition of ionotropic receptors. Journal of Neurochemistry 1998, 70:1104-1113.
39. Felling R.J., Singer H.S. Neurobiology of tourette syndrome: current status and need for further investigation. Journal of Neuroscience 2011, 31:12387-12395.
40. Fellows S.J., Noth J. Grip force abnormalities in de novo Parkinson's disease. Movement Disorders 2004, 19:560-565.
41. Ferrari M., Termine C., Franciotta D., Castiglioni E., Pagani A., Lanzi G., Marino F., Lecchini S., Cosentino M., Balottin U. Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. Journal of Psychiatric Research 2008, 43:24-29.
42. Fillmore M.T., Rush C.R., Hays L. Acute effects of cocaine in two models of inhibitory control: implications of non-linear dose effects. Addiction 2006, 101:1323-1332.
43. Findley D.B., Leckman J.F., Katsovich L., Lin H., Zhang H., Grantz H., Otka J., Lombroso P.J., King R.A. Development of the Yale Children's Global Stress Index (YCGSI) and its application in children and adolescents ith Tourette's syndrome and obsessive-compulsive disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2003, 42:450-457.
44. Fitzgerald P.B., Brown T.L., Daskalakis Z.J., Kulkarni J. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology (Berlin) 2002, 162:74-81.
45. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.M., Drebing C., Nagamoto H., Bickford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophrenia Bulletin 1987, 13:669-678.
46. Friedhoff A.J. Receptor maturation in pathogenesis and treatment of Tourette syndrome. Advances in Neurology 1982, 35:133-140.
47. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Research Reviews 1998, 26:148-153.
48. Ganos C., Roessner V., Münchau A. The functional anatomy of Gilles de la Tourette syndrome 2012, 37:1050-1662.
49. Genro J.P., Kieling C., Rohde L.A., Hutz M.H. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses. Expert Review of Neurotherapeutics 2010, 10:587-601.
50. George M.S., Robertson M.M., Costa D.C., Ell P.J., Trimble M.R., Pilowsky L., Verhoeff N.P. Dopamine receptor availability in Tourette's syndrome. Psychiatry Research 1994, 55:193-203.
51. Gilbert D.L., Christian B.T., Gelfand M.J., Shi B., Mantil J., Sallee F.R. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 2006, 67:1695-1697.
52. Gilbert D.L., Dure L., Sethuraman G., Raab D., Lane J., Sallee F.R. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003, 60:606-611.
53. Gilbert D.L., Sethuraman G., Sine L., Peters S., Sallee F.R. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000, 54:1310-1315.
54. Goetz C.G., Stebbins G.T., Thelen J.A. Talipexole and adult Gilles de la Tourette's syndrome: double-blind placebo-controlled clinical trial. Movement Disorders 1994, 9:315-317.
55. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
56. Grace A.A. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug and Alcohol Dependence 1995, 37:111-129.
57. Green B. Focus on aripiprazole. Current Medical Research and Opinion 2004, 20:207-213.
58. Greimel E., Wanderer S., Rothenberger A., Herpertz-Dahlmann B., Konrad K., Roessner V. Attentional performance in children and adolescents with tic disorder and co-occurring attention-deficit/hyperactivity disorder: new insights from a 2×2 factorial design study. Journal of Abnormal Child Psychology 2011, 39:819-828.
59. Grunder G., Carlsson A., Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of General Psychiatry 2003, 60:974-977.
60. Harris K., Singer H.S. Tic disorders: neural circuits, neurochemistry, and neuroimmunology. Journal of Child Neurology 2006, 21:678-689.
61. Haugbøl S., Pinborg L.H., Regeur L., Hansen E.S., Bolwig T.G., Nielsen F.A., Svarer C., Skovgaard L.T., Knudsen G.M. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. International Journal of Neuropsychopharmacology 2007, 10:245-252.
62. Heinz A., Knable M.B., Wolf S.S., Jones D.W., Gorey J.G., Hyde T.M., Weinberger D.R. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 1998, 51:1069-1074.
63. Heise K.-F., Steven B., Liuzzi G., Thomalla G., Jonas M., Müller-Vahl K., Sauseng P., Münchau A., Gerloff C., Hummel F.C. Altered modulation of intracortical excitability during movement preparation in Gilles de la Tourette syndrome. Brain 2010, 133:580-590.
64. Hemmerle A.M., Herman J.P., Seroogy K.B. Stress depression and Parkinson's disease. Experimental Neurology 2012, 233:79-86.
65. Hershey T., Black K.J., Hartlein J.M., Barch D.M., Braver T.S., Carl J.L., Perlmutter J.S. Cognitive-pharmacologic functional magnetic resonance imaging in Tourette syndrome: a pilot study. Biological Psychiatry 2004, 55:916-925.
66. Hipólito L., Sánchez-Catalán M.-J., Zornoza T., Polache A., Granero L. Locomotor stimulant effects of acute and repeated intrategmental injections of salsolinol in rats: role of mu-opioid receptors. Psychopharmacology (Berlin) 2010, 209:1-11.
67. Hoekstra P.J., Anderson G.M., Limburg P.C., Korf J., Kallenberg C.G.M., Minderaa R.B. Neurobiology and neuroimmunology of Tourette's syndrome: an update. Celluar and Molecular Life Sciences 2004, 61:886-898.
68. Hoffman D.C., Donovan H. D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology (Berlin) 1994, 115:447-453.
69. Hwang W.-J., Yao W.-J., Fu Y.-K., Yang A.-S. [99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome. Psychiatry Research 2008, 162:159-166.
70. Inglis F.M., Moghaddam B. Dopaminergic innervation of the amygdala is highly responsive to stress. Journal of Neurochemistry 1999, 72:1088-1094.
71. Johannes S., Wieringa B.M., Mantey M., Nager W., Rada D., Müller-Vahl K.R., Emrich H.M., Dengler R., Münte T.F., Dietrich D. Altered inhibition of motor responses in Tourette syndrome and obsessive-compulsive disorder. Acta Neurologica Scandinavica 2001, 104:36-43.
72. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 2002, 441:137-140.
73. Kawikova I., Leckman J.F., Kronig H., Katsovich L., Bessen D.E., Ghebremichael M., Bothwell A.L.M. Decreased numbers of regulatory T cells suggest impaired immune tolerance in children with tourette syndrome: a preliminary study. Biological Psychiatry 2007, 61:273-278.
74. King D., Zigmond M.J., Finlay J.M. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience 1997, 77:141-153.
75. Kurlan R., Crespi G., Coffey B., Mueller-Vahl K., Koval S., Wunderlich G. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Movement Disorders 2012, 27:775-778.
76. Kurlan R., Johnson D., Kaplan E.L. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008, 121:1188-1197.
77. Kwak C., Dat Vuong K., Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Movement Disorders 2003, 18:1530-1533.
78. Leckman J.F. Tourette's syndrome. Lancet 2002, 360:1577-1586.
79. Leckman J.F., Bloch M.H., Smith M.E., Larabi D., Hampson M. Neurobiological substrates of Tourette's disorder. Journal of Child and Adolescent Psychopharmacology 2010, 20:237-247.
80. Leckman J.F., Katsovich L., Kawikova I., Lin H., Zhang H., Krönig H., Morshed S., Parveen S., Grantz H., Lombroso P.J., King R.A. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biological Psychiatry 2005, 57:667-673.
81. Leckman J.F., King R.A., Gilbert D.L., Coffey B.J., Singer H.S., Dure L.S., Grantz H., Katsovich L., Lin H., Lombroso P.J., Kawikova I., Johnson D.R., Kurlan R.M., Kaplan E.L. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. Journal of the American Academy of Child & Adolescent Psychiatry 2011, 50:108-118.e3.
82. Leslie D.L., Kozma L., Martin A., Landeros A., Katsovich L., King R.A., Leckman J.F. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. Journal of the American Academy of Child & Adolescent Psychiatry 2008, 47:1166-1172.
83. Liang L., DeLong M.R., Papa S.M. Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. Journal of Neuroscience 2008, 28:7537-7547.
84. Light G.A., Braff D.L. Human and animal studies of schizophrenia-related gating deficits. Current Psychiatry Reports 1999, 1:31-40.
85. Light G.A., Braff D.L. Measuring P50 suppression and prepulse inhibition in a single recording session. American Journal of Psychiatry 2001, 158:2066-2068.
86. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. American Journal of Psychiatry 2000, 157:767-771.
87. Lin H., Katsovich L., Ghebremichael M., Findley D.B., Grantz H., Lombroso P.J., King R.A., Zhang H., Leckman J.F. Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry 2007, 48:157-166.
88. Lipinski J.F., Sallee F.R., Jackson C., Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Movement Disorders 1997, 12:402-407.
89. Liposits Z., Paull W.K. Association of dopaminergic fibers with corticotropin releasing hormone (CRH)-synthesizing neurons in the paraventricular nucleus of the rat hypothalamus. Histochemistry 1989, 93:119-127.
90. Liu H., Dong F., Meng Z., Zhang B., Tan J., Wang Y. Evaluation of Tourette's syndrome by (99m)Tc-TRODAT-1 SPECT/CT imaging. Annals of Nuclear Medicine 2010, 24:515-521.
91. Lookingland, K.J., Moore, K.E., 2005. Hypothalamic dopaminergic neuroendocrine systems. In: Dunnett SB, Bentivoglio M, Björklund A, Hökfelt T (Eds.). Handbook of Chemical Neuroanatomy, Volume 21, Dopamine. Amsterdam: Elsevier.
92. Ludolph A.G., Kassubek J., Schmeck K., Glaser C., Wunderlich A., Buck A.K., Reske S.N., Fegert J.M., Mottaghy F.M. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. Neuroimage 2008, 41:718-727.
93. Macht M., Schwarz R., Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta Neurologica Scandinavica 2005, 111:95-101.
94. Malison R.T., McDougle C.J., van Dyck C.H., Scahill L., Baldwin R.M., Seibyl J.P., Price L.H., Leckman J.F., Innis R.B. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. American Journal of Psychiatry 1995, 152:1359-1361.
95. Martino D., Dale R.C., Gilbert D.L., Giovannoni G., Leckman J.F. Immunopathogenic mechanisms in tourette syndrome: a critical review. Movement Disorders 2009, 24:1267-1279.
96. McEwen B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiological Reviews 2007, 87:873-904.
97. McEwen B.S. Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Annals of the New York Academy of Sciences 2010, 1204(Suppl):E38-E59.
98. Mell L.K., Davis R.L., Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics 2005, 116:56-60.
99. Mena I., Miranda M., Hernandez M., et al. Dopamine transporter imaging in tourette syndrome: Evaluation by neurospect of trodat 1-tc99m. Movement Disorders 2004, 19:1282.
100. Meyer P., Bohnen N.I., Minoshima S., Koeppe R.A., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology 1999, 53:371-374.
101. Millar A., Smith D., Choueiry J., Fisher D., Albert P., Knott V. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience 2011, 180:148-156.
102. Millichap J.G., Yee M.M. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012, 129:330-337.
103. Minzer K., Lee O., Hong J.J., Singer H.S. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. Journal of the Neurological Sciences 2004, 219:55-61.
104. Moll G.H., Heinrich H., Trott G., Wirth S., Rothenberger A. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neuroscience Letters 2000, 284:121-125.
105. Mora F., Segovia G., Del Arco A., de Blas M., Garrido P. Stress, neurotransmitters, corticosterone and body-brain integration. Brain Research 2012, 1476:71-85.
106. Moser A., Scholz J., Nobbe F., Vieregge P., Böhme V., Bamberg H. Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. Journal of the Neurological Sciences 1995, 131:183-189.
107. Mravec B. Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: a review of recent developments. Physiological Research 2006, 55:353-364.
108. Müller, J., 2008. Dopamine and Cognitive control: flexibility and stability in a set-shifting-paradigm. Dissertation [in German], Technische Universität Dresden, Dresden.
109. Müller-Vahl K.R., Berding G., Brücke T., Kolbe H., Meyer G.J., Hundeshagen H., Dengler R., Knapp W.H., Emrich H.M. Dopamine transporter binding in Gilles de la Tourette syndrome. Journal of Neurology 2000, 247:514-520.
110. Müller-Vahl K.R., Berding G., Kolbe H., Meyer G.J., Hundeshagen H., Dengler R., Knapp W.H., Emrich H.M. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurologica Scandinavica 2000, 101:165-171.
111. Müller-Vahl K.R., Buddensiek N., Geomelas M., Emrich H.M. The influence of different food and drink on tics in Tourette syndrome. Acta Paediatrica 2008, 97:442-446.
112. Müller-Vahl K.R., Meyer G.J., Knapp W.H., Emrich H.M., Gielow P., Brücke T., Berding G. Serotonin transporter binding in Tourette Syndrome. Neuroscience Letters 2005, 385:120-125.
113. Musshoff F., Schmidt P., Dettmeyer R., Priemer F., Wittig H., Madea B. A systematic regional study of dopamine and dopamine-derived salsolinol and norsalsolinol levels in human brain areas. Forensic Science International 1999, 105:1-11.
114. Nardone R., Ausserer H., Bratti A., Covi M., Lochner P., Marth R., Tezzon F. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurologica Scandinavica 2006, 114:244-249.
115. Niwa T., Takeda N., Yoshizumi H., Tatematsu A., Yoshida M., Dostert P., Naoi M., Nagatsu T. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline novel endogenous amines, in parkinsonian and normal human brains. Biochemical and Biophysical Research Communications 1991, 177:603-609.
116. Nombela C., Pedreño-Molina J.L., Ros-Bernal F., Molina-Vilaplana J., Fdez-Villalba E., López-Coronado J., Herrero M.-T. Dopamine modulation affects the performance of parkinsonian patients in a precision motor task measured by an antropomorphic device. Human Movement Science 2012, 31:730-742.
117. Nowak D.A., Rothwell J., Topka H., Robertson M.M., Orth M. Grip force behavior in Gilles de la Tourette syndrome. Movement Disorders 2005, 20:217-223.
118. Onur ö.A., Piefke M., Lie C.-H., Thiel C.M., Fink G.R. Modulatory effects of levodopa on cognitive control in young but not in older subjects: a pharmacological fMRI study. Journal of Cognitive Neuroscience 2011, 23:2797-2810.
119. Oranje B., Gispen-de Wied C.C., Westenberg H.G.M., Kemner C., Verbaten M.N., Khan R.S. Increasing dopaminergic activity: effects of l-dopa and bromocriptine on human sensory gating. Journal of Psychopharmacology (Oxford) 2004, 18:388-394.
120. Orth M., Amann B., Robertson M.M., Rothwell J.C. Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 2005, 128:1292-1300.
121. Orth M., Rothwell J.C. Motor cortex excitability and comorbidity in Gilles de la Tourette syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2009, 80:29-34.
122. Pacheco R., Prado C.E., Barrientos M.J., Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. Journal of Neuroimmunology 2009, 216:8-19.
123. Pan J.-T., Lookingland K.J., Moore K.E. Differential effects of corticotropin-releasing hormone on central dopaminergic and noradrenergic neurons. Journal of Biomedical Science 1995, 2:50-56.
124. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., Fang Z.H., Lee B.J., Kim Y.H. Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neuroscience Research 2011, 71:335-340.
125. Párraga H.C., Párraga M.I., Harris D.K. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. International Journal of Psychiatry in Medicine 2007, 37:415-424.
126. Pascucci T., Ventura R., Latagliata E.C., Cabib S., Puglisi-Allegra S. The medial prefrontal cortex determines the accumbens dopamine response to stress through the opposing influences of norepinephrine and dopamine. Cerebral Cortex 2007, 17:2796-2804.
127. Pliszka S.R. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005, 57:1385-1390.
128. Porta M., Sassi M., Cavallazzi M., Fornari M., Brambilla A., Servello D. Tourette's syndrome and role of tetrabenazine: review and personal experience. Clinical Drug Investigation 2008, 28:443-459.
129. Price R.A., Leckman J.F., Pauls D.L., Cohen D.J., Kidd K.K. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins. Neurology 1986, 36:232-237.
130. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. Journal of Clinical Psychopharmacology 2008, 28:S39-S45.
131. Pringsheim, T., Steeves, T., 2011. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database of Systematic Reviews CD007990.
132. Priori A., Berardelli A., Inghilleri M., Accornero N., Manfredi M. Motor cortical inhibition and the dopaminergic system Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced Parkinsonism. Brain 1994, 117(Pt 2):317-323.
133. Pruessner J.C., Champagne F., Meaney M.J., Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. Journal of Neuroscience 2004, 24:2825-2831.
134. Rabey J.M., Oberman Z., Graff E., Korczyn A.D. Decreased dopamine uptake into platelet storage granules in Gilles de la Tourette disease. Biological Psychiatry 1995, 38:112-115.
135. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. American Journal of Psychiatry 2003, 160:1554-1565.
136. Rammsayer T., Stahl J. Sensorimotor effects of pergolide a dopamine agonist, in healthy subjects: a lateralized readiness potential study. Psychopharmacology (Berlin) 2006, 187:36-46.
137. Reimherr F.W., Wender P.H., Ebert M.H., Wood D.R. Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Research 1984, 11:71-78.
138. Rice M.E., Cragg S.J. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Research Reviews 2008, 58:303-313.
139. Richard J.M., Berridge K.C. Nucleus accumbens dopamine/glutamate interaction switches modes to generate desire versus dread: D(1) alone for appetitive eating but D(1) and D(2) together for fear. Journal of Neuroscience 2011, 31:12866-12879.
140. Rickards H. Functional neuroimaging in Tourette syndrome. Journal of Psychosomatic Research 2009, 67:575-584.
141. Riggin R.M., McCarthy M.J., Kissinger P.T. Identification of salsolinol as a major dopamine metabolite in the banana. Journal of Agricultural and Food Chemistry 1976, 24:189-191.
142. Robbins T.W. Chemical neuromodulation of frontal-executive functions in humans and other animals. Experimental Brain Research 2000, 133:130-138.
143. Robertson M.M. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. Journal of Psychosomatic Research 2008, 65:473-486.
144. Roessner V., Banaschewski T., Fillmer-Otte A., Becker A., Albrecht B., Uebel H., Sergeant J., Tannock R., Rothenberger A. Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders. Journal of Neural Transmission 2008, 115:235-239.
145. Roessner V., Becker A., Banaschewski T., Freeman R.D., Rothenberger A. Developmental psychopathology of children and adolescents with Tourette syndrome--impact of ADHD. European Child & Adolescent Psychiatry 2007, 16(Suppl 1):24-35.
146. Roessner V., Becker A., Banaschewski T., Rothenberger A. Executive functions in children with chronic tic disorders with/without ADHD: new insights. European Child & Adolescent Psychiatry 2007, 16(Suppl 1):36-44.
147. Roessner V., Becker A., Banaschewski T., Rothenberger A. Psychopathological profile in children with chronic tic disorder and co-existing ADHD: additive effects. Journal of Abnormal Child Psychology 2007, 35:79-85.
148. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., Strand G., Stern J.S., Termine C., Hoekstra P.J. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. European Child & Adolescent Psychiatry 2011, 20:173-196.
149. Roessner V., Robatzek M., Knapp G., Banaschewski T., Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Developmental Medicine & Child Neurology 2006, 48:616-621.
150. Roessner V., Walitza S., Riederer F., Hünnerkopf R., Rothenberger A., Gerlach M., Moser A. Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD?. Behavioral and Brain Functions 2007, 3:64.
151. Roussos P., Giakoumaki S.G., Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biological Psychiatry 2009, 66:997-1004.
152. Sagvolden, T., Johansen, E.B., Aase, H., Russell, V.A., 2005. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behavioral and Brain Science 28, 397-419; discussion 419-468.
153. Santello M., Muratori L., Gordon A.M. Control of multidigit grasping in Parkinson's disease: effect of object property predictability. Experimental Neurology 2004, 187:517-528.
154. Schlander M., Schwarz O., Rothenberger A., Roessner V. Tic disorders: administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample. European Psychiatry 2011, 26:370-374.
155. Schmitt K.C., Reith M.E.A. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Annals of the New York Academy of Sciences 2010, 1187:316-340.
156. Scholz J., Klingemann I., Moser A. Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2004, 75:634-636.
157. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends in Pharmacological Sciences 1994, 15:264-270.
158. Segovia G., Del Arco A., de Blas M., Garrido P., Mora F. Effects of an enriched environment on the release of dopamine in the prefrontal cortex produced by stress and on working memory during aging in the awake rat. Behavioural Brain Research 2008, 187:304-311.
159. Serra-Mestres J., Ring H.A., Costa D.C., Gacinovic S., Walker Z., Lees A.J., Robertson M.M., Trimble M.R. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica 2004, 109:140-146.
160. Serrien D.J., Nirkko A.C., Loher T.J., Lövblad K.-O., Burgunder J.-M., Wiesendanger M. Movement control of manipulative tasks in patients with Gilles de la Tourette syndrome. Brain 2002, 125:290-300.
161. Shale H., Fahn S., Mayeux R. Tics in a patient with Parkinson's disease. Movement Disorders 1986, 1:79-83.
162. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.-X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
163. Shaywitz B.A., Cohen D.J., Bowers M.B. CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. A preliminary report. Journal of Pediatric 1977, 90:67-71.
164. Shetty T., Chase T.N. Central monoamines and hyperkinase of childhood. Neurology 1976, 26:1000-1002.
165. Silva R.R., Munoz D.M., Barickman J., Friedhoff A.J. Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette's disorder. Journal of Child Psychology and Psychiatry 1995, 36:305-312.
166. Singer, H.S., in press. The neurochemistry of Tourette syndrome. In: Martino D, Leckman J (Eds.). Tourette Syndrome. New York: Oxford University Press.
167. Singer H.S., Hahn I.H., Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology 1991, 30:558-562.
168. Singer H.S., Szymanski S., Giuliano J., Yokoi F., Dogan A.S., Brasic J.R., Zhou Y., Grace A.A., Wong D.F. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. American Journal of Psychiatry 2002, 159:1329-1336.
169. Singer H.S., Tune L.E., Butler I.J., Zaczek R., Coyle J.T. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome. Advances in Neurology 1982, 35:177-183.
170. Smith L.K., Jadavji N.M., Colwell K.L., Katrina Perehudoff S., Metz G.A. Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. European Journal of Neuroscience 2008, 27:2133-2146.
171. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behavioural Brain Research 2002, 130:65-71.
172. Stamenkovic M., Schindler S.D., Asenbaum S., Neumeister A., Willeit M., Willinger U., de Zwaan M., Riederer F., Aschauer H.N., Kasper S. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [(123)I]-beta-CIT SPECt-study. European Neuropsychopharmacology 2001, 11:69-74.
173. Steeves T.D.L., Ko J.H., Kideckel D.M., Rusjan P., Houle S., Sandor P., Lang A.E., Strafella A.P. Extrastriatal dopaminergic dysfunction in tourette syndrome. Annals of Neurology 2010, 67:170-181.
174. Strolin Benedetti M., Dostert P., Carminati P. Influence of food intake on the enantiomeric composition of urinary salsolinol in man. Journal of Neural Transmission. General Section 1989, 78:43-51.
175. Swain J.E., Scahill L., Lombroso P.J., King R.A., Leckman J.F. Tourette syndrome and tic disorders: a decade of progress. Journal of the American Academy of Child & Adolescent Psychiatry 2007, 46:947-968.
176. Swedo S.E., Leonard H.L., Garvey M., Mittleman B., Allen A.J., Perlmutter S., Lougee L., Dow S., Zamkoff J., Dubbert B.K. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. American Journal of Psychiatry 1998, 155:264-271.
177. Sweet R.D., Bruun R., Shapiro E., Shapiro A.K. Presynaptic catecholamine antagonists as treatment for Tourette syndrome, Effects of alpha methyl para tyrosine and tetrabenazine. Archives of General Psychiatry 1974, 31:857-861.
178. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Archives of General Psychiatry 1994, 51:139-154.
179. Swerdlow N.R., Karban B., Ploum Y., Sharp R., Geyer M.A., Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an fMRI-friendly startle paradigm. Biological Psychiatry 2001, 50:578-585.
180. Swerdlow N.R., Platten A., Shoemaker J., Pitcher L., Auerbach P. Effects of pergolide on sensorimotor gating of the startle reflex in rats. Psychopharmacology (Berlin) 2001, 158:230-240.
181. Swerdlow N.R., Bongiovanni M.J., Tochen L., Shoemaker J.M. Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette syndrome. Psychopharmacology (Berlin) 2006, 186:246-254.
182. Swerdlow N.R., Krupin A.S., Bongiovanni M.J., Shoemaker J.M., Goins J.C., Hammer R.P. Heritable differences in the dopaminergic regulation of behavior in rats: relationship to D2-like receptor G-protein function. Neuropsychopharmacology 2006, 31:721-729.
183. Swerdlow N.R., Sutherland A.N. Using animal models to develop therapeutics for Tourette Syndrome. Pharmacology & Therapeutics 2005, 108:281-293.
184. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology 2005, 515:10-19.
185. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., Okada M. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology 2012, 62:765-774.
186. Thind K.K., Goldsmith P.C. Corticotropin-releasing factor neurons innervate dopamine neurons in the periventricular hypothalamus of juvenile macaques, synaptic evidence for a possible companion neurotransmitter. Neuroendocrinology 1989, 50:351-358.
187. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., Mertens P., Benabid A.-L., Pollak P., Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Archives of Neurology 2004, 61:1705-1709.
188. Tokimura H., Di Lazzaro V., Tokimura Y., Oliviero A., Profice P., Insola A., Mazzone P., Tonali P., Rothwell J.C. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. Journal of Physiology (London) 2000, 523(Pt 2):503-513.
189. Tourette's-Syndrome-Study-Group, 2002. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58, 527-536.
190. Tripp G., Wickens J.R. Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. Journal of Child Psychology and Psychiatry 2008, 49:691-704.
191. Tripp G., Wickens J.R. Neurobiology of ADHD. Neuropharmacology 2009, 57:579-589.
192. Turjanski N., Sawle G.V., Playford E.D., Weeks R., Lammerstma A.A., Lees A.J., Brooks D.J. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 1994, 57:688-692.
193. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. European Journal of Pharmacology 1995, 294:577-583.
194. Wagner C.K., Eaton M.J., Moore K.E., Lookingland K.J. Efferent projections from the region of the medial zona incerta containing A13 dopaminergic neurons: a PHA-L anterograde tract-tracing study in the rat. Brain Research 1995, 677:229-237.
195. Wanderer S., Roessner V., Freeman R., Bock N., Rothenberger A., Becker A. Relationship of obsessive-compulsive disorder to age-related comorbidity in children and adolescents with Tourette syndrome. Journal of Developmental and Behavioral Pediatrics 2012, 33:124-133.
196. Wolf S.S., Jones D.W., Knable M.B., Gorey J.G., Lee K.S., Hyde T.M., Coppola R., Weinberger D.R. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996, 273:1225-1227.
197. Wong D.F., Brasić J.R., Singer H.S., Schretlen D.J., Kuwabara H., Zhou Y., Nandi A., Maris M.A., Alexander M., Ye W., Rousset O., Kumar A., Szabo Z., Gjedde A., Grace A.A. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008, 33:1239-1251.
198. Wong D.F., Singer H.S., Brandt J., Shaya E., Chen C., Brown J., Kimball A.W., Gjedde A., Dannals R.F., Ravert H.T., Wilson P.D., Wagner H.N. D2-like dopamine receptor density in Tourette syndrome measured by PET. Journal of Nuclear Medicine 1997, 38:1243-1247.
199. Xie G., Ye J.-H. Salsolinol facilitates glutamatergic transmission to dopamine neurons in the posterior ventral tegmental area of rats. PLoS ONE 2012, 7:e36716.
200. Yamato T., Yamasaki S., Misumi Y., Kino M., Obata T., Aomine M. Modulation of the stress response by coffee: an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neuroscience Letters 2002, 332:87-90.
201. Yeh C.-B., Lee C.-S., Ma K.-H., Lee M.-S., Chang C.-J., Huang W.-S. Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging. Psychiatry Research 2007, 156:75-82.
202. Yoon D.Y., Gause C.D., Leckman J.F., Singer H.S. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. Journal of the Neurological Sciences 2007, 255:50-56.
203. Zheng K.S., Dorfman B.J., Christos P.J., Khadem N.R., Henchcliffe C., Piboolnurak P., Nirenberg M.J. Clinical characteristics of exacerbations in Parkinson disease. Neurologist 2012, 18:120-124.
204. Zhu J., Reith M.E.A. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS & Neurological Disorders - Drug Targets 2008, 7:393-409.
205. Ziemann U., Tergau F., Bruns D., Baudewig J., Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalography and Clinical Neurophysiology 1997, 105:430-437.
206. Zou L.-P., Wang Y., Zhang L.-P., Zhao J.-B., Lu J.-F., Liu Q., Wang H.-Y. Tourette syndrome and excitatory substances: is there a connection?. Child's Nervous System 2011, 27:793-802.